Resources
CMS Semaglutide Obesity Coverage
Letter to CMS on the need for obesity treatment coverage.
CMS Semaglutide Coverage Expansion Could Save Millions of Lives, Advocates Say
44 organizations across various disease states support an expansion of semaglutide coverage for Medicare and Medicaid patients.
Alternative Funding Programs
Alternative funding programs come at a significant cost to patients and the health care system.
Post-Approval Indications and Clinical Trials for Cardiovascular Drugs: Some Implications of the U.S. Inflation Reduction Act
To describe the historical baseline landscape of cardiovascular drug post-approval activity, including the number and timing of post-approval clinical trials and approved indications. The US Inflation Reduction Act of 2022 (IRA) Drug Price Negotiation Program (DPNP) and its Maximum Fair Prices (MFPs) will affect incentives for investment in post-approval activity such as clinical trials for […]
Alternative Funding Programs
Alternative funding programs come at a significant cost to patients and the health care system.
La Pesada Carga De La Hipertensión
Infographic
Presión en Aumento: La Necesidad Urgente de Innovar en el Tratamiento de la Hipertensión
En la próxima década, unos 25 millones de adultos estadounidenses desarrollarán hipertensión, a pesar de que esta enfermedad potencialmente mortal es fácil de diagnosticar y tratar.
#1 Cause of Death for Black Americans
Social media graphic
55% of Hypertension Patients
Social media graphic
Let’s Make Hypertension History
Social media graphic
Medicare Part D
The Extra Help program provides financial assistance to low-income and limited-income people enrolled in Medicare Part D prescription drug coverage.
What Price Negotiation Could Mean for New Heart Medications
Lower out-of-pocket prescription drugs costs spread more manageably across the calendar year. That’s what patients and policymakers alike hope to get from the Inflation Reduction Act.